Cipla’s Synchrobreathe (SB), a state-of-the-art breath-actuated inhaler, which will bring relief to millions of South Africans with Obstructive Airway Disease
Cipla today announced that it is currently developing an innovative inhaler, which will bring important benefits for South African physicians, patients and healthcare professionals on managing Obstructive Airway Diseases (OAD). This novel, breath-actuated inhaler (BAI), called Synchrobreathe is expected to reach the local market in fourth quarter 2015, and will be launched first in South Africa.
This is according to Paul Miller, CEO of Cipla Medpro – the third largest pharmaceutical manufacturer in South Africa, who says that Synchrobreathe will be welcomed by patients and physicians, because the inhaler holds three key benefits for the treatment of OAD.
Firstly, It is very simple to use and eliminates coordination challenges, which is the biggest issue faced by South African patients using conventional pressurised metered dose inhalers, says Miller. “Secondly the inspiratory flow required to trigger the inhaler mechanism is low, which makes it attractive to a large number of patients, whether young, elderly or patients suffering from severe conditions. And finally, Synchrobreathe is a breath-actuated inhaler with a built-in dose counter, which allows patients to track doses, thereby encouraging patient compliance.”
He points to a recent report by the Global Initiative for Asthma, which indicates that South Africa has the world’s fourth highest asthma death rate among five to 35 year olds. Of the estimated 3.9 million South Africans with asthma, 1.5% die of this condition annually.
Miller says that South Africa has amongst the highest asthma mortality rates in the world. “As a leading company in the area of respiratory health in South Africa, we are proud to announce the development of this innovation. The new product is in line with our commitment to bring innovative products and inhalers to best fit physicians’ and patients’ needs, thereby advancing healthcare for all”.
Frank Pieters, Global Head of Respiratory for Cipla said, “Simple and intuitive, Synchrobreathe is an innovation in managing respiratory disease. Synchrobreathe is attractive for patients as the inhaler is easy to use effectively. Equally importantly, Synchrobreathe will help cut the time healthcare providers need to spend to train patients in correct inhaler use. With this simple inhaler, the healthcare professional knows the patient will be able to use it easily and get the full benefit from every dose.”
Miller adds that Cipla has been at the forefront of innovation for inhalation therapy over the last 40 years with its respiratory products being available in over 100 countries. “Cipla further prides itself on having end-to-end capabilities across respiratory care, covering the value chain from active pharmaceutical ingredient (API), formulation, inhalers development and manufacturing to medical and patient education,” concludes Miller.
The development of Synchrobreathe was first announced at the South Africa Thoracic Society (SATS) Conference in Cape Town, South Africa (7-10 August 2015).
In the interest of our patients, in accordance with South African law and our commitment to expertise, MediHub cannot subscribe to the practice of online diagnosis. Please consult a medical professional for specific medical advice. If you have any major concerns, please see your doctor for an assessment. If you have any cause for concern, your GP will be able to direct you to the appropriate specialists.